News
3 Warren Buffett Stocks for Retirees
Warren Buffett is arguably the most revered investor on the planet. Over the course of more than six decades he's turned less than $10,000 into a net worth of nearly $79 billion. What's truly....
This Marijuana Stock Is On an 8-Day Losing Streak -- Is It Time to Buy?
Over the trailing year, there's arguably been no better-performing industry than marijuana and marijuana stocks. A majority of pot stocks have moved significantly higher over the past year, with a....
12 Flu Season Facts You Need to Know
Fall is officially here, and that usually means three things: pumpkin-spiced everything is back in style, our lush trees are about to become leafless sticks, and that sniffle and cough could be....
3 Top Marijuana Stocks to Buy This Fall
Marijuana stocks weren't all that hot in the first half of 2017. The situation began to turn around for several leading marijuana stocks in the summer, though. What's the outlook for fall? Pretty....
AbbVie's Unfazed by the Risk of Generic Humira
Over 60% of AbbVie Inc.’s (NYSE: ABBV) sales come from demand for Humira -- an autoimmune-disease drug prescribed to patients with a variety of conditions -- that racks up sales of $16 billion per....
Why Novavax, Inc. Could Be a Gold Mine for Growth Investors
If you had the misfortune to buy Novavax (NASDAQ: NVAX) stock in July 2015 and held on, around 90% of your investment would have been wiped out. Ouch. Even if you had bought the biotech stock at....
3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
One great thing about the biotech industry is that there are nearly always some winners. Regardless of what's going on in the world or in the broader market, at least a few biotech stocks are....
Better Buy: Kimberly-Clark Corp. vs. Johnson & Johnson
There aren't many companies that can grow sales and profits through a wide range of market conditions. But both Kimberly-Clark (NYSE: KMB), the consumer goods specialist, and Johnson & Johnson....
Oddly, Juno Therapeutics Is Jumping 11.3% Today
Despite a 6.1 million-share follow-on public stock offering, shares of Juno Therapeutics (NASDAQ: JUNO) are rallying 11.3% higher at 3 p.m. EDT.Juno Therapeutics shares have been rallying since....
Why Exelixis, Inc. Slumped Today
Exelixis (NASDAQ: EXEL) is down 12.3% at 2:18 p.m. EDT after an analyst at Leerink Partners downgraded the biotech to market perform. Management also sold some shares, which could be contributing....
This Trial Failure Dropped Versartis Inc 86.6% and Lifted Ascendis Pharma 51.4%
Shares of biopharma Versartis (NASDAQ: VSAR) crashed nearly 87% Friday after somavaratan, the company's lead drug candidate, did not meet its primary endpoint in the phase 3 Velocity trial. The....
AstraZeneca Stock Upgraded: What You Need to Know
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one....
Why Is Cash-Rich Gilead Sciences, Inc. Borrowing $3 Billion?
Last week, Gilead Sciences (NASDAQ: GILD) announced that it was borrowing $3 billion. That's billion with a "B."The company doesn't really need the money. It was sitting on $36.6 billion in cash,....
3 Big Biotech Stocks to Buy This Fall
A change in season presents a good time to look for great stocks to buy. And one of the best places to look is in the biotech industry. Biotech stocks in general are trouncing the S&P 500....
These 3 Stocks Are Priced for Perfection. Can They Deliver?
You expect a top-ranked football team to play well every game. You expect the Kentucky Derby winner to place in the Preakness Stakes. And you expect a stock with a high valuation to generate....
Better Buy: Celgene Corporation vs. Merck & Co., Inc.
Based on recent history, Celgene Corporation (NASDAQ: CELG) and Merck & Co. (NYSE: MRK) stocks don't even belong in the same league. Celgene stock is up more than 270% over the past five....
3 Biotech Stocks With Major Catalysts Incoming
Axovant Sciences Ltd (NASDAQ: AXON) and PTC Therapeutics, Inc. (NASDAQ: PTCT) have drugs in late-stage development that could propel them to profitability over the next few years. Gilead Sciences,....
Why Intercept Pharmaceuticals Is Tumbling Today
Intercept Pharmaceuticals (NASDAQ: ICPT), a biotech focused on liver diseases, fell 21% as of 3:26 p.m. EDT Thursday. The fall is traceable to a safety announcement released by the FDA that warns....
Why Calgon Carbon, Kindred Healthcare, and Impax Laboratories Jumped Today
Thursday was a down day for the stock market, but major benchmarks managed to limit their losses to modest amounts of less than half a percent. Investors looked at a wide variety of different....
Billionaires Are Gobbling Up This Beaten-Down Biotech Stock: Should You?
Julian and Felix Baker of the $15.6 billion hedge fund Baker Bros. Advisors are well-known for their uncanny ability to unearth hidden gems in biotech and biopharma. So when I noticed that the....
3 Stocks to Help You Make Money in Retirement
Especially if you're looking forward to a long retirement, you'll still want to own some stocks after you've cashed your final paycheck. Unlike cash or many bonds these days, returns from stocks....
3 Small-Cap Biotech Stocks to Buy This Fall
Hundreds of small-cap biotech stocks are available for investors. All of them come with relatively high levels of risk. With that high risk, though, also comes the potential for high returns.But....
Pfizer and Johnson & Johnson's Brewing Brawl Gets Real
Pfizer (NYSE: PFE) took direct aim at Johnson & Johnson (NYSE: JNJ) last year when it won FDA approval for Inflectra, a biosimilar to Johnson & Johnson's multi-billion dollar per year....
Here's Why Arbutus Biopharma Corp. Stock Soared Today
Shares of Arbutus Biopharma Corp. (NASDAQ: ABUS) rode some mighty coattails today. This morning, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced highly positive data for a candidate that....
Alnylam Notches a Game-Changing RNAi Win
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is researching therapies that can treat genetic diseases by interfering with gene expression. Though Alnylam has yet to validate its approach with a....